TBPH - Kapitalisasi marang volume dodolan Theravance Biopharma Inc

Logo korporat perusahaan Theravance Biopharma Inc (TBPH)

Risks for Theravance Biopharma (TBPH) are linked to a dependence on Trelegy payments and regulatory pressure. This chart in the GURU.Markets terminal illustrates the revenue multiple level, which currently stands at 8.50. Business stability is supported by passive income from respiratory drug patents, while the environmental profile meets international standards through production outsourcing.

TBPH: Multiplikator P/S Theravance 04.07.2022 - 10.10.2026

Rincian analitis perusahaan Theravance Corp (TBPH)

- rega saham lan konsensus proyeksi valuasi:
Ringkesan analitik perusahaan:Theravance Biopharma, Inc. TBPH
Produk dadi Theravance

The P/S multiple reflects the market value of a business relative to its generated revenue, allowing an investor to assess the degree of overpayment for an asset regardless of current profitability. By analyzing the price-to-sales ratio, one can evaluate the monetization efficiency of Theravance Biopharma (TBPH) patent rights, where stable royalties from the GSK partnership create a predictable cash flow without operational distribution costs.

Perusahaan pesaing

HLN (Haleon) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Kenvue Inc KVUE|Verona Pharma Corp - Rasio rega marang pendapatan|MENS: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan Ligand Pharmaceuticals LGND|Amneal Pharmaceuticals Inc (AMRX) - Rasio rega marang pendapatan|Perrigo Company PLC - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan alvotech.com|Multiplikator P/S Liquidia Technologies|Rasio rega marang pendapatan Galapagos Genomics (GLPG)|ANIP: Rasio rega marang dodolan|Multiplikator P/S MNKD (MannKind Corp)|Koefisien rega marang pendapatan Amphastar (AMPH)|PCRX: Kapitalisasi marang pendapatan|SPRY - Multiplikator P/S|AQST (Aquestive Therapeutics) - Kapitalisasi marang pendapatan|scPharmaceuticals, Inc. (SCPH) - Multiplikator P/S|Kapitalisasi marang pendapatan TECX|Multiplikator P/S Tonix Pharma|Kapitalisasi marang pendapatan SXTC (SXT Pharmaceuticals)|EPRX: Rasio rega marang dodolan|BioHarvest Sciences - Kapitalisasi marang pendapatan|EXOZ: Rasio kapitalisasi marang pendapatan|ORMP - Rasio rega marang pendapatan|ENTX: Rasio rega marang pendapatan|HYFT: Multiplikator P/S|Kapitalisasi marang pendapatan ABVC BioPharma Inc|CPIX (Cumberland Corp) - Multiplikator P/S|Multiplikator P/S quantumbiopharma.com|Multiplikator P/S FGEN|Kapitalisasi marang pendapatan Telomir Pharmaceuticals, Inc. TELO|Multiplikator P/S RANI (Rani Therapeutics)|SNYR (Synergy CHC Corp) - Rasio rega marang dodolan|RLYB: Kapitalisasi marang pendapatan|lexariabioscience.com (LEXX) - Kapitalisasi marang pendapatan|Pulmatrix Inc (PULM) - Rasio rega marang pendapatan|PTHL: Kapitalisasi marang volume dodolan|APM (Aptorum Group Ltd) - Multiplikator P/S|Lyra Therapeutics Inc (LYRA) - Koefisien rega marang pendapatan|Multiplikator P/S IBO|Kapitalisasi marang volume dodolan TNFA|cbdMD, Inc. - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan PRFX|Altamira Therapeutics Ltd. - Multiplikator P/S|LIPO: Rasio rega marang pendapatan|OPTN: Multiplikator P/S|Rasio rega marang dodolan PIRS (Pieris Pharmaceuticals)|PROC (Procaps) - Multiplikator P/S|PTPI (Petros Pharmaceuticals Inc) - Kapitalisasi marang volume dodolan|Multiplikator P/S QLI|SLRN - Rega marang dodolan|Multiplikator P/S TFFP (TFF Pharmaceuticals, Inc)